M. Fatih ÖNSÜZ, Ahmet TOPUZOĞLU, ZEYNEP BİLGİ, MUSA YILMAZ, Nagihan AMUK, Fevziye FAHRİDİN

Bir tıp fakültesinde kadın hastalıkları ve doğum stajını yapmış öğrencilerin HPV aşısı hakkında bilgi düzeyleri ve tutumlarının değerlendirilmesi

AMAÇ: Araştırmanın amacı, bir tıp fakültesinde kadın hastalıkları ve doğum stajı yapmış öğrencilerin HPV aşısı hakkındaki bilgilerini ve mesleki yaşamlarında aşıyı hastalara önerme eğilimlerini belirlemektir. YÖNTEM: Tanımlayıcı tipteki araştırma bir tıp fakültesinde Kadın Hastalıkları ve Doğum stajını yapmış 166 öğrenci ile yürütüldü. Araştırmanın verileri 3 bölüm halinde hazırlanmış olan ve 30 sorudan oluşan bir anket yolu ile toplandı. İstatistiksel analizde tanımlayıcı istatistikler kullanıldı. BULGULAR: Katılımcı öğrencilerin %55,4’ü kendini HPV aşısı konusunda bilgili hissettiğini belirtirken, %72,9’u HPV’nin kadınlar için daha önemli olduğunu belirtti. Katılımcıların %95,8’i HPV aşısını hastalarına önermeyi düşündüğünü belirtirken, en çok (%51,6) ergenlik çağındaki genç kızlara önermeyi düşünüyorlardı. Öğrencilerin %80,5’i HPV aşısının bedava olmasının önerme ihtimallerini arttıracağını belirtmişti. Aşıyı önerenlerin en çekindikleri noktalar aşının çok pahalı, maliyet etkili olmaması (%51,6) ve korunmasız, riskli cinsel ilişkiyi teşvik edebileceğini (%45,9) düşünmeleriydi. SONUÇ: Araştırmamızda HPV aşısının öğrenciler arasında mesleki olarak kabul gördüğü ve aşının önerilmesindeki en önemli çekincenin aşının maliyet etkililiği olduğu belirlenmiştir.

The evaluation of the knowledge levels and attitudes of medical students who have accomplished obstetric and gynaecological diseases internship in a medical school about human papilloma virus vaccine

AIM: Aim of the study was to determine medical school students’ knowledge levels and attitudes who accomplished Obstetric and Gynecology clerkship in a medical school about HPV vaccination and intention to suggest HPV vaccine to their patients. METHOD: This descriptive study was carried out in a medical school among 166 medical students accomplishing their internship in the Obstetrics and Gynaecological Diseases Department. Study data had been collected by questionnaire which had three part and 30 question. The data were evaluated by descriptive statistics. RESULTS: Fifty five point four of the students stated that they felt informed about HPV vaccine, 72.9% of them stated that HPV was more serious for women. 95.8% of the participants thought they would suggest HPV vaccine to their patients and the most proposed group was adolescent girls (51.6%). 80.5% of students stated their possibility to suggest the vaccine would increase in case the vaccine would be free. The most important drawback points of the students in suggesting the vaccine to their patients were thinking high priced and not cost effectiveness of the vaccine (51.6%) and inducing unprotected, risky sexual intercourses (45.9%). CONCLUSION: In this study we determine the professional acception of HPV vaccine between students. Also we determine the most important factor in suggesting the HPV vaccine is the cost effectiveness of it.

PDF

___

1 Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in highgrade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89: 101-105.
2 Einstein MH, Goldberg GL. Human papillomavirus and cervical neoplasia. Cancer Invest. 2002; 20: 1080-1085.
3 Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527.
4 Christensen ND. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs. 2005; 10: 5-19.
5 Kahn JA, Bernstein DI. Human papillomavirus vaccines. Pediatr Infect Dis J. 2003; 22: 443.
6 Shaw AR. Human papillomavirus vaccines in development: If they’re successful in clinical trials, how will they be implemented? Gynecologic Oncology. 2005; 99: S246-248.
7 Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247-1255.
8 Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347: 1645- 1651.
9 Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised doubleblind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271-278.
10 Ault KA. Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369: 1861-1868.
11 Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369: 2161-2170.
12 Wright TC, Van Damme P, Schmitt HJ, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine. 2006; 24(3): 122-131.
13 Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis. 2000; 27: 49-52.
14 Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. J Adolesc Health. 2005; 37(6): 17-23.
15 Wong LP, Sam IC. Ethnically diverse female university students’ knowledge and attitudes toward human papillomavirus (HPV), HPV vaccination and cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2010; 148: 90-95.
16 Esposito S, Bosis S, Pelucchi C, et al. Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention. Vaccine. 2007; 25: 6437-6446.
17 Duval B, Gilca V, McNeil S, et al. Vaccination against human papillomavirus: A baseline survey of Canadian clinicians’ knowledge, attitudes and beliefs. Vaccine. 2007; 25: 7841- 7847.
18 Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians’ intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005; 37: 502-510.
19 Riedesel JM, Rosenthal SL, Zimet GD, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol. 2005; 18: 391-398.
20 Aldrich T, Becker D, Garcia SG, Lara D. Mexican physicians’ knowledge and attitudes about the human papillomavirus and cervical cancer: a national survey. Sex Transm Infect. 2005; 81: 135-141.
21 Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex. Transm. Dis. 2003; 30: 774-778.
22 Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006; 117: 1486-1493.
23 Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int. J. STD AIDS. 2003; 14: 300-306.
24 De Carvalho NS, Teixeira LM, Pradel EM, Gabardo J, Joly C, Urbanetz AA. Vaccinating against HPV: Physicians’ and medical students’ point of view. Vaccine. 2009; 27: 2637-2640.
25 Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology. 2002; 13: 631-639.
26 Garnett GP, Dubin G, Slaoui M, Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect. 2004; 80: 24-29.
27 Parkin DM, Bray F. Chapter 2: The burden of HPV related cancers. Vaccine. 2006; 24(3); 11- 25.
28 Katz IT, Wright AA. Preventing cervical cancer in the developing world. N Engl J Med. 2006; 354: 1110.
29 Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. Human Papilloma Virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health. 2007; 7: 304.
30 Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004; 36: 11-19.
31 Harper DM. Why am I scared of HPV? CA Cancer J Clin. 2004; 54: 245-247.
32 Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290: 781-789.
33 Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604-615.
34 Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003; 9: 37-48.
35 Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007: 40; 108-115.
36 Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10 to 15 year old adolescents. J Low Genit Tract Dis. 2004: 8; 188-194.
37 Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med. 2004: 58; 1405-1413.
38 Zimet GD, Mays RM, Sturm LA, Ravert AA, Perkins SM, Juliar BE. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. Arch Pediatr Adolesc Med. 2005: 159; 132-137.